SIMPLIFIED TOTAL LIQUID VENTILATOR

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41HL064987-01A2
Agency Tracking Number: HL064987
Amount: $185,643.00
Phase: Phase I
Program: STTR
Awards Year: 2002
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
MC3, INC.
MC3, INC., 3550 W LIBERTY RD, STE 3, ANN ARBOR, MI, 48103
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 KATHRYN OSTERHOLZER
 (734) 995-9089
 KOSTER@MC3CORP.COM
Business Contact
 SCOTT MERZ
Phone: (734) 995-9089
Email: KOSTER@MC3CORP.COM
Research Institution
 UNIV OF MICHIGAN
 UNIV OF MICHIGAN
ANN ARBOR, MI, 48109
 Nonprofit college or university
Abstract
The acute respiratory distress syndrome (ARDS) is a severe, life-threatening disease process, which affects approximately 150,000 patients per year with an associated 30-50 percent mortality rate. Periluorocarbons are inert, colorless, low surface tension liquids that can carry large quantities of oxygen and carbon dioxide. Clinical studies are currently exploring the safety and effectiveness of Partial Liquid Ventilation (PLy), in which the periluorocarbon-filled lung is gas-ventilated, in the setting of ARDS. However, there are a number of features, which suggest that the very different technique of Total Liquid Ventilation (TLV), in which the lungs are ventilated with perfluorocarbon using a liquid ventilating device, will be more effective from a biophysical and physiologic perspective. Previously designed liquid ventilators have been complex, have required large volumes of the expensive pert fluorocarbon for priming, and were not suitable for clinical use or human trial testing. The current proposal is directed at developing a clinically suitable simplified liquid ventilator for testing, characterizing, and improving the mechanical and gas exchange properties and capabilities in-vitro, and subsequently in well established in-vivo large animal model. These data will be critical toward demonstrating the clinical relevance and thus the commercial feasibility of this device.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government